Article Text

Download PDFPDF
Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.



Does switching to aripiprazole from olanzapine improve metabolic status in overweight people with schizophrenia or schizoaffective disorder?


Patients with schizophrenia or schizoaffective disorder (DSM-IV-TR) treated with olanzapine only (10–20 mg/day for 1–24 months). Inclusion criteria: body mass index ⩾27; Clinical Global Impressions-Severity score ⩽4. Main exclusion criteria: other axis I disorder; diabetes; neurological condition or mental retardation; suicide risk; alcohol or drug dependence or electroconvulsive therapy 3 months prior to study; previous failure to respond to aripiprazole; clinically significant ECG, blood result or vital sign; pregnant, breastfeeding or not reliably using contraception for the duration of the study plus 4 weeks after study completion.


Multinational (countries not stated); recruitment 30 March 2004 to 8 August 2006.


Switch to aripiprazole (n = 88) or continued olanzapine (n = 85) for 16 weeks. Switch participants received up to 15 mg/day aripiprazole across 2 weeks while decreasing olanzapine dose to nil, then 15 mg/day (fixed for 4 weeks) and then flexible dose …

View Full Text


  • Source of funding: Bristol-Myers Squibb (Princeton, NJ, USA) and Otsuka Pharmaceuticals Co Ltd (Tokyo, Japan).


  • Competing interests: TJRL has received research funds and been on advisory boards and speaker bureaus for both Eli Lilly (olanzapine) and BMS (aripiprazole).